Scholarlink

<p>The development of metabolic dysfunction-associated steatotic liver disease (MASLD), and its progression to metabolic dysfunction-associated steatohepatitis (MASH), is triggered and aggravated by obesity and related metabolic diseases. Hence, therapeutic strategies for obesity and diabetes are employed in the clinical management of MASLD and MASH. However, most of the antiobesity and antidiabetic drugs have been withdrawn from the market due to a lack of sustainable drug effects and undesirable side effects. Prior to the approval of resmetirom by the United States Food and Drug Administration in 2024, there were no specific treatments for MASLD and MASH. Therefore, this stresses the importance of developing improved and effective disease-specific treatment strategies to combat MASLD and MASH. MASLD and MASH are characterized by hepatocyte damage, chronic low-grade systemic inflammation, and abnormalities in lipid metabolism. Inflammation and oxidative stress are key mediators of high-fat diet-induced steatohepatitis and obesity. Identifying biomarkers involved in these processes could aid in the development of targeted treatment for MASLD and MASH. In this review, targeted treatment strategies for obesity are discussed in relation to the possibility of the same being used in obesity-related steatotic liver diseases (SLDs).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月25日

查看全文
  • Thendo I. Mabuda,
  • Nicole R. S. Sibuyi,
  • Adewale O. Fadaka,
  • Mervin Meyer,
  • Abram M. Madiehe,
  • Kwazikwakhe B. Gabuza

摘要

The development of metabolic dysfunction-associated steatotic liver disease (MASLD), and its progression to metabolic dysfunction-associated steatohepatitis (MASH), is triggered and aggravated by obesity and related metabolic diseases. Hence, therapeutic strategies for obesity and diabetes are employed in the clinical management of MASLD and MASH. However, most of the antiobesity and antidiabetic drugs have been withdrawn from the market due to a lack of sustainable drug effects and undesirable side effects. Prior to the approval of resmetirom by the United States Food and Drug Administration in 2024, there were no specific treatments for MASLD and MASH. Therefore, this stresses the importance of developing improved and effective disease-specific treatment strategies to combat MASLD and MASH. MASLD and MASH are characterized by hepatocyte damage, chronic low-grade systemic inflammation, and abnormalities in lipid metabolism. Inflammation and oxidative stress are key mediators of high-fat diet-induced steatohepatitis and obesity. Identifying biomarkers involved in these processes could aid in the development of targeted treatment for MASLD and MASH. In this review, targeted treatment strategies for obesity are discussed in relation to the possibility of the same being used in obesity-related steatotic liver diseases (SLDs).